Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.Coronavirus Vaccine Update: The Pennsylvania-based drugmaker had previously estimated it would begin the phase two and three trials during summer this year.Inovio said during the earnings call it was exploring partnerships beyond the United States and Europe for its vaccine candidate, and expected repetitive revenue similar to those from the flu vaccine.The company reiterated its previous estimate of producing one million doses this year and 100 million by 2021, and said it planned to obtain …read more
Source:: Yahoo Finance
